Fibrotic metabolic dysfunction-associated steatohepatitis
Disease1 paper1 finding
- Human trial1
Interventions
1Dasatinib + quercetin
downin humans1
1 study
Dasatinib + quercetin
downin humans1
Dasatinib + quercetin decreases fibrotic metabolic dysfunction-associated steatohepatitis in humans (47% versus 7%).
Human trialfibrotic MASHliverdasatinib 100 mg per day plus quercetin 1,000 mg per daythree consecutive days per week over 3 weeks, repeated across three 7-week cycles
Dasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial · Nature metabolism · 1 Oct 2026
Latest
1Human trialCellular senescence
Dasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.